STAT+: FDA reverses course, agrees to review Moderna’s flu vaccine

The FDA has reversed its earlier decision and will now review Moderna's mRNA-based flu vaccine, which it had previously declined. This announcement was made by the company on Wednesday. The reversal has been characterized as a "surprise rejection" and has raised concerns among experts regarding its implications for the vaccine industry. Experts have noted that the FDA's actions may create a "destructive precedent" that could undermine future vaccine development in the U.S. The situation reflects broader issues within the FDA, which has faced criticism for its handling of vaccine approvals. Moderna expressed optimism that its new flu shot could be available this year following the FDA's decision to review the vaccine. The reversal is seen as a positive development for drugmakers and vaccine developers, although it highlights ongoing chaos within the agency. The FDA's decision to review the flu vaccine has been described as moving the goalposts on Moderna, leading to uncertainty for other vaccine developers. The implications of the FDA's reversal extend beyond Moderna, as it may affect the confidence of other pharmaceutical companies in the regulatory process. The decision to review the flu vaccine is significant in the context of ongoing discussions about vaccine innovation and regulatory standards in the U.S. The situation underscores the complexities and challenges faced by the FDA in balancing safety, efficacy, and the need for timely vaccine availability.